A Study on the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of SKB500 in Subjects with Advanced Solid Tumors

PHASE1RecruitingINTERVENTIONAL

Enrollment

180

Participants

Timeline

Start Date

December 13, 2024

Primary Completion Date

July 31, 2025

Study Completion Date

December 31, 2028

Conditions

Advanced Solid Tumors

Interventions

DRUG

SKB500

The administration route of SKB500 is intravenous infusion, with a dosing frequency of Q3W.

Trial Locations (1)

RECRUITING

JILIN Cancer Hospital, Jilin

All Listed Sponsors

lead

Sichuan Kelun Pharmaceutical Research Institute Co., Ltd.

INDUSTRY